Wave Life Sciences Ltd. (1U5.F)
- Previous Close
4.6600 - Open
4.6400 - Bid 4.3800 x --
- Ask 4.4800 x --
- Day's Range
4.6400 - 4.6400 - 52 Week Range
3.1600 - 6.2000 - Volume
1,000 - Avg. Volume
107 - Market Cap (intraday)
569.954M - Beta (5Y Monthly) -1.08
- PE Ratio (TTM)
-- - EPS (TTM)
-0.5000 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
9.86
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.
www.wavelifesciences.comRecent News: 1U5.F
Performance Overview: 1U5.F
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 1U5.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 1U5.F
Valuation Measures
Market Cap
572.41M
Enterprise Value
415.23M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.67
Price/Book (mrq)
15.39
Enterprise Value/Revenue
3.66
Enterprise Value/EBITDA
-7.06
Financial Highlights
Profitability and Income Statement
Profit Margin
-50.76%
Return on Assets (ttm)
-20.17%
Return on Equity (ttm)
-1,118.17%
Revenue (ttm)
113.31M
Net Income Avi to Common (ttm)
-57.51M
Diluted EPS (ttm)
-0.5000
Balance Sheet and Cash Flow
Total Cash (mrq)
200.35M
Total Debt/Equity (mrq)
67.61%
Levered Free Cash Flow (ttm)
64.11M
Research Analysis: 1U5.F
Company Insights: 1U5.F
1U5.F does not have Company Insights